REGENXBIO ANNOUNCES PHASE I/II TRIAL OF RGX-202, A NOVEL GENE THERAPY CANDIDATE FOR DUCHENNE MUSCULAR DYSTROPHY, IS ACTIVE AND RECRUITING PATIENTS

REGENXBIO is recruiting participants aged 4-11 years old for their microdystrophin gene therapy trial, as well as participants aged 0-11 years for an observational study to understand the prevalence of anti-AAV8 and AAV9 antibodies in boys with Duchenne. See below REGENXBIO press release

https://regenxbio.gcs-web.com/news-releases/news-release-details/regenxbio-announces-phase-iii-trial-rgx-202-novel-gene-therapy